Tristen Park, MD
Assistant Professor of Surgery (Oncology, Breast)
Research & Publications
Biography
News
Research Summary
As a medical student, Dr. Park witnessed the dramatic impact of cancer immunotherapy on refractory late stage metastatic disease at the National Cancer Institute. In Dr. Steven Rosenberg's clinical immunotherapy service, stage 4 cancer patients undergo complete regression of their tumors and remain disease-free for decades. This fascinated Dr. Park and guided her research and career trajectory into surgical oncology with a research emphasis on cancer immunotherapy. After medical school, she returned to the NCI as a surgical oncology and clinical immunotherapy fellow treating these very same patients whose remarkable responses she had first witnessed. During this time, she published 6 papers in basic and translational cancer immunotherapy at the NCI. Dr. Park chose to focus her clinical specialty in breast surgical oncology and completed a fellowship at Duke University. She is currently an Assistant Professor of Surgery at Yale Medical School, Smilow Cancer Hospital, and Director of the Prospective Breast Tumor Biorepository.
Dr. Park has published basic science studies on the topic of improving immunotherapy using novel artificial microRNA constructs against checkpoint inhibitors, and additionally has published on characterizing new immunotherapy targets in a variety of cancers including breast cancer.
Coauthors
Research Interests
Breast; Breast Diseases; Immunotherapy
Selected Publications
- Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm D, Pusztai L. Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC. Journal Of Clinical Oncology 2022, 40: 516-516. DOI: 10.1200/jco.2022.40.16_suppl.516.
- ASO Visual Abstract: Association of Medicaid Expansion on Postmastectomy Reconstruction RatesLe Blanc J, Golshan M, Lannin D, Greenup R, Berger E, Saridakis A, Horowitz N, Zanieski G, Avraham T, Mastrioanni M, Park T. ASO Visual Abstract: Association of Medicaid Expansion on Postmastectomy Reconstruction Rates. Annals Of Surgical Oncology 2022, 29: 2191-2192. DOI: 10.1245/s10434-021-10944-9.
- Abstract P3-09-05: Predictive markers of response to durvalumab concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) neoadjuvant therapy for triple negative breast cancer (TNBC)Blenman K, Li X, Marczyk M, O'Meara T, Yaghoobi V, Gunasekharan V, Park T, Rimm D, Pusztai L. Abstract P3-09-05: Predictive markers of response to durvalumab concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) neoadjuvant therapy for triple negative breast cancer (TNBC). Cancer Research 2020, 80: p3-09-05-p3-09-05. DOI: 10.1158/1538-7445.sabcs19-p3-09-05.
- The Association of Extent of Axillary Surgery and Survival in Women with N2–3 Invasive Breast CancerPark TS, Thomas SM, Rosenberger LH, Fayanju OM, Plichta JK, Blitzblau RC, Ong CT, Hyslop T, Hwang ES, Greenup RA. The Association of Extent of Axillary Surgery and Survival in Women with N2–3 Invasive Breast Cancer. Annals Of Surgical Oncology 2018, 25: 3019-3029. PMID: 29978365, PMCID: PMC6474911, DOI: 10.1245/s10434-018-6587-2.
- Patient Age and Tumor Subtype Predict the Extent of Axillary Surgery Among Breast Cancer Patients Eligible for the American College of Surgeons Oncology Group Trial Z0011Ong CT, Thomas SM, Blitzblau RC, Fayanju OM, Park TS, Plichta JK, Rosenberger LH, Hyslop T, Shelley Hwang E, Greenup RA. Patient Age and Tumor Subtype Predict the Extent of Axillary Surgery Among Breast Cancer Patients Eligible for the American College of Surgeons Oncology Group Trial Z0011. Annals Of Surgical Oncology 2017, 24: 3559-3566. PMID: 28879416, PMCID: PMC5994237, DOI: 10.1245/s10434-017-6075-0.
- Role of axillary node dissection after mastectomy with positive sentinel nodes.Park T, Thomas S, Greenup R, Hwang E. Role of axillary node dissection after mastectomy with positive sentinel nodes. Journal Of Clinical Oncology 2017, 35: 554-554. DOI: 10.1200/jco.2017.35.15_suppl.554.
- Temporal associations between prognostic indicators and overall survival after breast cancer.Plichta J, Thomas S, Fayanju O, Rosenberger L, Park T, Hyslop T, Greenup R, Hwang E. Temporal associations between prognostic indicators and overall survival after breast cancer. Journal Of Clinical Oncology 2017, 35: e18144-e18144. DOI: 10.1200/jco.2017.35.15_suppl.e18144.
- Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma PatientsPark TS, Phan GQ, Yang JC, Kammula U, Hughes MS, Trebska-McGowan K, Morton KE, White DE, Rosenberg SA, Sherry RM. Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients. Annals Of Surgical Oncology 2017, 24: 947-951. PMID: 28144760, PMCID: PMC5339323, DOI: 10.1245/s10434-017-5768-8.
- Current Trends in the Management of Ductal Carcinoma In Situ.Park TS, Hwang ES. Current Trends in the Management of Ductal Carcinoma In Situ. Oncology 2016, 30: 823-31. PMID: 27633413.
- MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 CasesKerkar SP, Wang ZF, Lasota J, Park T, Patel K, Groh E, Rosenberg SA, Miettinen MM. MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases. Journal Of Immunotherapy 2016, 39: 181-187. PMID: 27070449, PMCID: PMC4831141, DOI: 10.1097/cji.0000000000000119.
- Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic CancersPark TS, Groh EM, Patel K, Kerkar SP, Lee CC, Rosenberg SA. Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers. Journal Of Immunotherapy 2016, 39: 1-7. PMID: 26641256, PMCID: PMC6453128, DOI: 10.1097/cji.0000000000000101.
- Use of the piggyBac Transposon to Create Stable Packaging Cell Lines for the Production of Clinical-Grade Self-Inactivating γ-Retroviral VectorsFeldman SA, Xu H, Black MA, Park TS, Robbins PF, Kochenderfer JN, Morgan RA, Rosenberg SA. Use of the piggyBac Transposon to Create Stable Packaging Cell Lines for the Production of Clinical-Grade Self-Inactivating γ-Retroviral Vectors. Human Gene Therapy 2014, 25: 253-260. PMID: 25072603, PMCID: PMC4142856, DOI: 10.1089/hgtb.2014.071.
- Gamma-Retroviral Vector Design for the Co-Expression of Artificial microRNAs and Therapeutic ProteinsPark TS, Abate-Daga D, Zhang L, Zheng Z, Morgan RA. Gamma-Retroviral Vector Design for the Co-Expression of Artificial microRNAs and Therapeutic Proteins. Nucleic Acid Therapeutics 2014, 24: 356-363. PMID: 25019196, PMCID: PMC4162432, DOI: 10.1089/nat.2014.0486.
- Treating cancer with genetically engineered T cellsPark TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends In Biotechnology 2011, 29: 550-557. PMID: 21663987, PMCID: PMC3193849, DOI: 10.1016/j.tibtech.2011.04.009.
- Routine imaging to detect recurrences in high-risk melanoma patients.Park T, Lagisetty K, Sherry R, Yang J, Hughes M, Morton K, White D, Klionsky Y, Rosenberg S, Phan G. Routine imaging to detect recurrences in high-risk melanoma patients. Journal Of Clinical Oncology 2011, 29: 8576-8576. DOI: 10.1200/jco.2011.29.15_suppl.8576.